For the first time in years, beekeepers have genuinely new chemistry to consider against Varroa destructor rather than another rotation of the same handful of miticides. Between September 2025 and early 2026, the EPA registered two treatments built on mechanisms never before available commercially — an RNA interference product and the first amino-acid-based miticide — while USDA researchers separately reported progress on restoring effectiveness to a drug resistance has been eroding for years. None of these are widely established yet, and beekeepers should weigh that limited real-world track record honestly before switching a proven rotation.
Key Takeaways
- Norroa (active ingredient vadescana), from GreenLight Biosciences, is the first EPA-registered RNA interference (RNAi) treatment for Varroa, registered in September 2025 and now available nationally.
- Vadescana works by triggering RNAi against a gene specific to Varroa mites, placing it in IRAC Group 35 — a genuinely new mode of action distinct from every existing miticide class.
- Field trials cited by GreenLight reported extended mite control of up to 18 weeks per application, with no reported effect on bees, humans, or non-target species.
- A separate new product from CH Biotech, registered around March 2026, uses L-glutamic acid as its active ingredient — the first amino-acid-based Varroa miticide to reach EPA registration.
- USDA ARS researchers reported 2026 progress on a resistance-inhibiting compound that, combined with amitraz, aims to restore effectiveness against amitraz-resistant Varroa populations — still research-stage, not yet a commercial product.
Table of Contents
- Norroa (Vadescana): The First RNAi Varroa Treatment
- The New Glutamic-Acid Miticide
- USDA’s Amitraz Resistance-Inhibitor Research
- How the Three Compare
- Why “Mode of Action” Is the Number That Actually Matters
- How New Are These, Really?
- Frequently Asked Questions
Norroa (Vadescana): The First RNAi Varroa Treatment
GreenLight Biosciences announced EPA registration of Norroa, its RNAi-based Varroa treatment, in late September 2025, after the EPA had proposed registering the active ingredient, vadescana, in May 2025. Vadescana works through RNA interference — a naturally occurring biological process, here engineered to precisely target a gene specific to Varroa mites, ultimately disrupting the mite’s ability to reproduce. It’s classified under Insecticide Resistance Action Committee Group 35, a genuinely new mode of action beekeepers haven’t had access to before, which matters directly for resistance management: rotating between different modes of action, not just different product names, is the core strategy for slowing resistance development in any pest population.
GreenLight Biosciences describes vadescana’s effects as “highly specific to varroa mites,” reporting the product “does not affect humans or other non-target organisms, including bees and threatened or endangered species,” with the nucleic acids breaking down quickly in the environment after application.
Replicated field trials across multiple U.S. regions, cited in GreenLight’s own reporting and covered by trade outlets including PR Newswire and AgriBusiness Global, demonstrated extended mite control lasting up to 18 weeks per application — notably longer than the several-week window typical of many existing miticide treatments. As of 2026, Norroa is reported as available in all states.
The New Glutamic-Acid Miticide
Separately, a new miticide from CH Biotech built around L-glutamic acid, an amino acid, received EPA registration around March 2026 — the first amino-acid-based Varroa treatment to reach commercial registration. This represents a genuinely different chemical category from both the RNAi mechanism behind Norroa and the synthetic acaricides (amitraz, thymol-based products) beekeepers already use, giving beekeepers a third distinct chemistry option to factor into a resistance-management rotation. As with Norroa, real-world adoption and long-term field performance data are still limited given how recently the product reached market — early availability, not an established multi-year track record.
USDA’s Amitraz Resistance-Inhibitor Research
Amitraz, the active ingredient in widely used products like Apivar strips, has faced growing documented resistance in Varroa populations in various regions over recent years, eroding its previously reliable effectiveness. USDA Agricultural Research Service scientists reported 2026 progress on a compound designed to inhibit the specific resistance mechanism mites have developed, restoring amitraz’s effectiveness when the two are combined. This work remains at the research stage — it has not yet reached commercial registration or field availability — but it directly addresses a genuinely urgent problem for beekeepers currently relying on amitraz as a rotation mainstay and finding it less reliable than it used to be.
This independent beekeeping channel’s explainer walks through vadescana’s mechanism and what the RNAi approach means in practice for a working beekeeper’s treatment plan:
How the Three Compare
| Treatment | Mechanism | EPA Status | How It Differs From Existing Options |
|---|---|---|---|
| Norroa (vadescana) | RNA interference targeting a Varroa-specific gene | Registered September 2025; available nationally as of 2026 | Entirely new mode of action (IRAC Group 35); up to 18 weeks control per application in cited field trials |
| CH Biotech glutamic-acid miticide | Amino-acid-based acaricidal action | Registered ~March 2026 | First amino-acid miticide; distinct chemistry from both RNAi and existing synthetic acaricides like amitraz or thymol |
| USDA amitraz resistance-inhibitor | Restores amitraz effectiveness by blocking the mite’s resistance mechanism | Research stage; not yet commercially registered | Extends the useful life of an existing, already-familiar treatment rather than introducing a new one |
None of these replaces the need for a rotation strategy across different modes of action, and none should be assumed to work as well in a specific operation as it did in cited field trials until a beekeeper has tested it directly against their own mite-count data — the same due diligence any experienced beekeeper already applies to established options like oxalic acid or HopGuard.
Why “Mode of Action” Is the Number That Actually Matters
The Insecticide Resistance Action Committee (IRAC) numbering system exists specifically to help applicators avoid a common, resistance-accelerating mistake: rotating between products with different brand names that actually share the same underlying biochemical mode of action, which does little to slow resistance development since the mites are facing the same selective pressure regardless of the label on the box. Amitraz-based products fall into one IRAC group; thymol and other essential-oil-based treatments work through different mechanisms entirely; oxalic acid’s mode of action is different again. Vadescana’s classification into IRAC Group 35 specifically means it doesn’t share cross-resistance risk with any treatment already in a beekeeper’s rotation — which is precisely why its arrival matters more for long-term resistance management strategy than its raw effectiveness numbers alone would suggest, even before accounting for how new and lightly field-tested it still is.
How New Are These, Really?
It’s worth stating plainly: both Norroa and the glutamic-acid miticide are genuinely new to market, with real EPA registrations behind them, but neither has the years of widespread field use and independently accumulated beekeeper experience that older standbys like amitraz, thymol, or oxalic acid have built up. Early field trial results are promising on their own terms, but promising trial data and multi-year, large-scale real-world performance are not the same thing. Beekeepers considering either product should treat 2026 as genuinely early days for both, verify current registration and availability with their state’s applicable regulations, and weigh a new option as an addition to a resistance-management rotation rather than a wholesale replacement for treatments already known to work reliably in their specific region and operation. Practically, that means checking a state department of agriculture’s current pesticide registration database or the product label itself before ordering either treatment, since EPA federal registration is a necessary but not automatically sufficient condition — some states require an additional state-level registration step before a given product can be legally applied within that state’s borders, a detail that applies to any newly registered agricultural treatment, not just these two specifically.
Frequently Asked Questions
What is Norroa and how does it work against Varroa mites?
Norroa is GreenLight Biosciences’ RNA interference (RNAi) treatment, using the active ingredient vadescana to target a gene specific to Varroa mites and disrupt their reproduction — the first RNAi-based Varroa product to reach EPA registration, in September 2025.
Is Norroa safe for honeybees?
GreenLight Biosciences reports the treatment is highly specific to Varroa mites and does not affect bees, humans, or other non-target organisms, based on the field trial data cited in its own registration materials and trade press coverage.
What is the new amino-acid Varroa treatment?
A glutamic-acid-based miticide from CH Biotech, registered by the EPA around March 2026 — the first Varroa treatment built on an amino-acid active ingredient rather than a synthetic acaricide or biological mechanism like RNAi.
Is amitraz resistance a widespread problem?
Documented resistance has grown in various Varroa populations in recent years, prompting USDA ARS research into a resistance-inhibiting compound designed to restore amitraz’s effectiveness when combined with it, though that research has not yet reached commercial availability.
Should beekeepers switch immediately to these new treatments?
Not without caution. Both newly registered products have limited real-world track records compared to established options, and the standard resistance-management advice — rotate modes of action, verify results against your own mite counts — applies just as much to brand-new chemistry as to anything already familiar.
Where can I find more established Varroa treatment guides on this site?
See our guides to oxalic acid vaporization, Apivar amitraz strips, and Apiguard thymol gel.
